Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Magdalena Petryk"'
Autor:
Michael L. Grossbard, Mala Varma, Elizabeth D. Ames, Magdalena Petryk, Seth M. Cohen, Peter Kozuch
Publikováno v:
The Oncologist. 11:1100-1117
Learning Objectives After completing this course, the reader will be able to: Outline the definition and classification of MALT lymphoma.Summarize the current understanding of the pathogenesis of MALT lymphoma.Articulate treatment options for patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38dddf04102a433da4ad4fef2276c194
https://doi.org/10.1634/theoncologist.11-10-1100
https://doi.org/10.1634/theoncologist.11-10-1100
Publikováno v:
Surgical Clinics of North America. 81:683-690
Gemcitabine is a promising agent for metastatic pancreatic cancer. Before gemcitabine, survival time with metastatic disease averaged 3 to 5 months, and objective responses were few. Even when tumors underwent objective regression, questions about th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3ed9a7224904ed704aa62efa69a08e9
https://doi.org/10.1016/s0039-6109(05)70153-5
https://doi.org/10.1016/s0039-6109(05)70153-5
Autor:
Magdalena Petryk, Michael L. Grossbard
Publikováno v:
Clinical Lymphoma. 1:186-194
The development of rituximab, an anti-CD20 monoclonal antibody, represents a revolutionary advance in the therapy of hematological malignancies. Rituximab was approved in 1997 by the Food and Drug Administration for the treatment of relapsed or refra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbcd56a5d6b5b9b6943162f29285cdd4
https://doi.org/10.3816/clm.2000.n.015
https://doi.org/10.3816/clm.2000.n.015
Publikováno v:
Hematology/oncology clinics of North America. 16(1)
Phase II trials of combination chemotherapies have shown encouraging palliative benefit, objective response rates, and survival outcomes. Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc03fa42b9e6a90e5ae1a48a406fba5e
https://pubmed.ncbi.nlm.nih.gov/12063823
https://pubmed.ncbi.nlm.nih.gov/12063823
Autor:
Magdalena Petryk, Michael L. Grossbard
Publikováno v:
The oncologist. 6(4)
This article reviews highlights in the field of hematologic malignancies presented at the 2001 annual meeting of the American Society of Clinical Oncology. Targeted therapies continue to proceed from the laboratory to the clinic. Monoclonal antibody-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7ce2e64c257e5f9fd75167f6d4745fa
https://pubmed.ncbi.nlm.nih.gov/11524549
https://pubmed.ncbi.nlm.nih.gov/11524549
Publikováno v:
The Surgical clinics of North America. 81(3)
Chemoradiotherapy for unresectable LAPA is associated with a median survival time of 9 months or more and manageable toxic side effects. Experience with RT-FSP provides evidence that chemoradiotherapy may extend survival time with or without resectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d371272b05f79bfab9c25eab7f9ba791
https://pubmed.ncbi.nlm.nih.gov/11459282
https://pubmed.ncbi.nlm.nih.gov/11459282
Publikováno v:
Clinical Lymphoma; Dec2000, Vol. 1 Issue 3, p186-194, 9p